Journal article

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

James A Tumlin, Raghavan Murugan, Adam M Deane, Marlies Ostermann, Laurence W Busse, Kealy R Ham, Kianoush Kashani, Harold M Szerlip, John R Prowle, Azra Bihorac, Kevin W Finkel, Alexander Zarbock, Lui G Forni, Shannan J Lynch, Jeff Jensen, Stew Kroll, Lakhmir S Chawla, George F Tidmarsh, Rinaldo Bellomo

Critical Care Medicine | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018

Grants

Funding Acknowledgements

Shannan Lynch, Jeff Jensen, Stew Kroll, Lakhmir Chawla, and George Tidmarsh are employees of La Jolla Pharmaceutical Company. The Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) trial was funded and supported by La Jolla Pharmaceutical Company. All other authors participated in the ATHOS-3 trial as investigators and work(ed) at institutions that were funded by La Jolla Pharmaceutical Company in support of the ATHOS-3 trial. Additionally, John R. Prowle has received consultancy fees and speaker honoraria from Nikkiso Europe GmbH and speaker honoraria from Baxter, Inc. Raghavan Murugan was awarded a research grant from La Jolla Pharmaceutical Company, and has received consulting fees from Beckman and Coulter, Inc and Bioporto, Inc. Kianoush Kashani has received a travel grant from La Jolla Pharmaceutical Company for the ATHOS-3 investigator meeting. Marlies Ostermann has received research funding and speaker honoraria from Fresenius Medical Care. Alexander Zarbock has received consulting fees from Astellas and Quark Pharmaceutical; speaker honoraria from Astute Medical, Baxter, Frensenius, and Braun; and grant support from Astute Medical and Quark Pharmaceutical. James Tumlin has received research grant support from La Jolla Pharmaceutical Company. Kevin Finkel will be a member of the La Jolla Pharmaceutical Company Speakers Bureau in 2018. Lawrence Busse has received consulting fees from La Jolla Pharmaceutical Company. Lui Forni has received research funding and honoraria from Fresenius, Baxter Gambro Renal, OrthoClinical Diagnostics, and La Jolla Pharmaceutical Company. Drs. Tumlin, Murugan, Deane, Ham, Szerlip, Prowle, Bihorac, Zarbock, and Bellomo's institutions received funding from La Jolla Pharmaceuticals. Drs. Tumlin and Kroll disclosed off-label product use of angiotensin II for circulatory shock. Drs. Busse, Forni, and Kroll received funding from La Jolla Pharmaceutical Company. Dr. Szerlip's institution also received funding from Baylor Research Institute. Dr. Finkel received funding from Alexion Pharmaceuticals (speakers bureau). Dr. Zarbock received funding from Baxter, Astute Medical, Fresenius, Braun, Astellas, and DFG. Dr. Forni also received funding from Ortho Clinical Diagnostics (honoraria). Drs. Lynch, Jensen, Kroll, Chawla, and Tidmarsh disclosed that they are employees of the trial sponsor (La Jolla Pharmaceutical Company). Dr. Tidmarsh disclosed work for hire. The remaining authors have disclosed that they do not have any potential conflicts of interest.